Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Long-term Consistency in Rotavirus Vaccine Protection: RV5 and RV1 Vaccine Effectiveness in US Children, 2012-2013
Clinical Infectious Diseases, Volume 61, No. 12, Year 2015
Notification
URL copied to clipboard!
Description
Background. Using a multicenter, active surveillance network from 2 rotavirus seasons (2012 and 2013), we assessed the vaccine effectiveness of RV5 (RotaTeq) and RV1 (Rotarix) rotavirus vaccines in preventing rotavirus gastroenteritis hospitalizations and emergency department (ED) visits for numerous demographic and secular strata. Methods. We enrolled children hospitalized or visiting the ED with acute gastroenteritis (AGE) for the 2012 and 2013 seasons at 7 medical institutions. Stool specimens were tested for rotavirus by enzyme immunoassay and genotyped, and rotavirus vaccination histories were compared for rotavirus-positive cases and rotavirus-negative AGE controls. We calculated the vaccine effectiveness (VE) for preventing rotavirus associated hospitalizations and ED visits for each vaccine, stratified by vaccine dose, season, clinical setting, age, predominant genotype, and ethnicity. Results. RV5-specific VE analyses included 2961 subjects, 402 rotavirus cases (14%) and 2559 rotavirus-negative AGE controls. RV1-specific VE analyses included 904 subjects, 100 rotavirus cases (11%), and 804 rotavirus-negative AGE controls. Over the 2 rotavirus seasons, the VE for a complete 3-dose vaccination with RV5 was 80% (confidence interval [CI], 74%-84%), and VE for a complete 2-dose vaccination with RV1 was 80% (CI, 68%-88%). Statistically significant VE was observed for each year of life for which sufficient data allowed analysis (7 years for RV5 and 3 years for RV1). Both vaccines provided statistically significant genotype-specific protection against predominant circulating rotavirus strains. Conclusions. In this large, geographically and demographically diverse sample of US children, we observed that RV5 and RV1 rotavirus vaccines each provided a lasting and broadly heterologous protection against rotavirus gastroenteritis. © 2015 Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors & Co-Authors
Payne, Daniel C.
United States, Atlanta
Centers for Disease Control and Prevention
Selvarangan, Rangaraj
United States, Kansas City
Children's Mercy Hospitals and Clinics
Azimi, Parvin H.
United States, Oakland
Ucsf Benioff Children's Hospital Oakland
Englund, Janet A.
United States, Seattle
Seattle Children's Hospital
Halasa, Natasha B.
United States, Nashville
Vanderbilt University Medical Center
Weinberg, Geoffrey A.
United States, Rochester
University of Rochester
Szilâgyi, Peter G.
United States, Rochester
University of Rochester
United States, Los Angeles
University of California, Los Angeles
Chappell, James D.
United States, Nashville
Vanderbilt University Medical Center
McNeal, Monica Malone
United States, Cincinnati
Cincinnati Children's Hospital Medical Center
Klein, Eileen J.
United States, Seattle
Seattle Children's Hospital
Harrison, Christopher J.
United States, Kansas City
Children's Mercy Hospitals and Clinics
Baker, Carol J.
United States, Houston
Baylor College of Medicine
Bernstein, David Isaac
United States, Cincinnati
Cincinnati Children's Hospital Medical Center
Tate, Jacqueline E.
United States, Atlanta
Centers for Disease Control and Prevention
Mijatovic-Rustempasic, Slavica
United States, Atlanta
Centers for Disease Control and Prevention
Esona, Mathew Dioh
United States, Atlanta
Centers for Disease Control and Prevention
Curns, Aaron T.
United States, Atlanta
Centers for Disease Control and Prevention
Bowen, Michael D.
United States, Atlanta
Centers for Disease Control and Prevention
Gentsch, Jon R.
United States, Atlanta
Centers for Disease Control and Prevention
Parashar, Umesh D.
United States, Atlanta
Centers for Disease Control and Prevention
Statistics
Citations: 76
Authors: 20
Affiliations: 10
Identifiers
Doi:
10.1093/cid/civ872
ISSN:
10584838
Research Areas
Genetics And Genomics
Maternal And Child Health